The present invention relates to novel compositions including a mixture of cadaverine, putrescine, spermine and spermidine at a concentration varying from 0.31 to 0.63 nmol per gram of composition, said composition also including agmatine at a concentration varying from 120 to 17,100 nmols per gram of composition, and to the uses thereof in treating diseases associated with the hyperproliferation of cells in a patient.
The present invention relates to novel compositions including a mixture of cadaverine, putrescine, and spermidine at a concentration of 0.3 to 0.6 nanomoles per gram of composition, said composition also including spermine at a concentration of 150 to 17,000 nanomoles per gram of composition, as well as to the uses thereof for treating a patient for diseases associated with cell hyperproliferation.
The present invention relates to a composition including less than 600 picomoles, in particular less than 400 picomoles, of biologically-active polyamines per gram of composition, to be used in the prevention or treatment of a patient, in particular a human being or an animal, for skin or mucosa conditions induced by radiotherapy.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A23L 1/00 - Aliments ou produits alimentaires; Leur préparation ou traitement (leur conservation en général A23L 3/00)
A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
The present invention relates to the use of a composition that comprises: at least one alkylglycerol; at least one inhibitor of the biosynthesis of polyamines; a carrier lean in biologically "active" polyamines; and optionally at least one antitumor agent; as a combination preparation for a simultaneous, separated or time-spread use, for making a drug for treating pathologies associated with angiogenesis dysfunction and/or tumor pathologies, wherein the total amount of biologically active polyamines ingested per day by the human or animal to whom said drug is administered does not exceed 30 nanomoles per kcal of ingested product, in particular 25 nanomoles per kcal of ingested product, more particularly 23 nanomoles per kcal of ingested product, and more particularly 20 nanomoles per kcal of ingested product.
A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
brevets